KRX 123
Latest Information Update: 21 Dec 2018
At a glance
- Originator Keryx Biopharmaceuticals
- Class
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 13 Dec 2018 Akebia Therapeutics merged with Keryx Pharmaceuticals to form Akebia Therapeutics
- 30 Apr 2007 Discontinued - Preclinical for Prostate cancer in Israel (unspecified route)
- 18 Nov 2002 This compound is still in active development